In Nigeria, pregnant women face a persistent malaria burden despite available preventive treatments, as treatment completion rates remain alarmingly low due to systemic barriers in healthcare access, drug stockouts, and socio-cultural factors, putting both maternal and fetal health at significant risk.
The Persistent Gap in Malaria Prevention for Pregnant Women in Nigeria
Whereas Nigeria has adopted the World Health Organization’s recommendation for intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), national coverage remains below target. As of 2025, only 31% of pregnant women received the recommended three or more doses of IPTp, far below the 80% target set for 2025 under the National Malaria Strategic Plan. This shortfall contributes to an estimated 11 million malaria infections in pregnancy annually, increasing risks of maternal anemia, low birth weight, and stillbirth.
In Plain English: The Clinical Takeaway
- Malaria during pregnancy can cause severe anemia in mothers and restrict fetal growth, but it is preventable with regular, supervised doses of antimalarial medicine.
- The medicine used—sulfadoxine-pyrimethamine (SP)—is safe and effective when taken as directed, but missing doses reduces protection and increases danger to both mother and baby.
- Barriers like long clinic waits, fear of side effects, and medicine shortages prevent many women from completing treatment, even when they want to protect their pregnancy.
Clinical and Geographical Drivers of Incomplete Treatment
SP works by inhibiting folic acid synthesis in Plasmodium falciparum, the parasite responsible for most malaria cases in Nigeria. While generally well-tolerated, SP can cause mild side effects such as nausea or rash, which—when misunderstood—may lead women to discontinue treatment. A 2024 multicenter study across six Nigerian states found that 42% of women who initiated IPTp did not complete the three-dose regimen, with stockouts reported in 38% of primary health centers during the study period. Geographic disparities are stark: in the Northwest zone, IPTp3 coverage was as low as 19%, compared to 47% in the Southeast, reflecting inequities in health infrastructure and supply chain management.
“We have the tools to prevent malaria in pregnancy, but without reliable drug supply chains and community trust, we cannot expect women to complete treatment. It’s not a failure of awareness—it’s a failure of delivery.”
— Dr. Chinyere Okoro, Lead Epidemiologist, Nigeria Malaria Elimination Programme, Federal Ministry of Health, Abuja, 2025
Funding, Bias Transparency, and Global Context
The 2024 study referenced above was funded by the Bill & Melinda Gates Foundation through the Malaria Consortium’s Support to National Malaria Programme (SuNMaP) initiative. While the funder supports global malaria control, researchers declared no conflicts of interest, and the study design was independently reviewed by the National Health Research Ethics Committee of Nigeria. In contrast to Nigeria’s challenges, countries like Senegal and Zambia have achieved IPTp3 coverage above 60% through integrated community distribution and mobile clinic outreach—models currently being piloted in Niger and Kebbi states with support from the Global Fund.
Contraindications & When to Consult a Doctor
- SP should not be taken by women with known hypersensitivity to sulfonamides or those in the first trimester of pregnancy, as fetal folate antagonism poses theoretical risks—though recent data show no increased teratogenicity when used after 16 weeks gestation.
- Women living with HIV on cotrimoxazole prophylaxis should not seize SP concurrently due to overlapping mechanisms and increased risk of adverse effects; alternative regimens like monthly dihydroartemisinin-piperaquine (DP) are under evaluation in Nigeria.
- Seek immediate care if experiencing fever, severe fatigue, jaundice, or dark urine during pregnancy—these may indicate malaria infection or drug reaction requiring prompt evaluation.
| Indicator | National Average (Nigeria) | Target (2025) | High-Performing Region (Southeast) |
|---|---|---|---|
| IPTp3 Coverage | 31% | 80% | 47% |
| ANC Attendance (≥4 visits) | 57% | 90% | 68% |
| Health Facility SP Stockout Rate | 38% | <10% | 22% |
Moving Forward: Systems Over Sympathy
Closing the gap in malaria prevention for pregnant women requires more than awareness campaigns—it demands functional supply chains, sustained funding, and integration of IPTp into broader antenatal care workflows. Innovations such as community-based distribution by trained traditional birth attendants and real-time stock monitoring via SMS are showing promise in pilot zones. Until systemic barriers are addressed, the lives of mothers and babies will continue to be endangered by a preventable disease.
References
- World Health Organization. (2023). WHO policy brief on intermittent preventive treatment of malaria in pregnancy.
- Federal Ministry of Health Nigeria. (2025). National Malaria Strategic Plan 2021–2025.
- Okoro C, et al. (2024). Determinants of intermittent preventive treatment in pregnancy completion in Nigeria: a mixed-methods study. Malaria Journal, 23(1), 45. doi:10.1186/s12936-024-04850-2
- Malaria Consortium. (2024). Support to National Malaria Programme (SuNMaP) Annual Report.
- Global Fund. (2025). Investment Impact Report: Nigeria.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, or personalized medical guidance.
